Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
Veracyte, Inc. (Nasdaq: VCYT) today announced that three posters showcasing new data from the company’s Afirma Genomic Sequencing Classifier (GSC) will be presented at the 2023 American Thyroid Association (ATA) Annual Meeting being held in Washington, DC from September 27 to October 1.
- Veracyte, Inc. (Nasdaq: VCYT) today announced that three posters showcasing new data from the company’s Afirma Genomic Sequencing Classifier (GSC) will be presented at the 2023 American Thyroid Association (ATA) Annual Meeting being held in Washington, DC from September 27 to October 1.
- Together, these abstracts offer novel insights into the molecular underpinnings of thyroid nodules and tumors based on whole-transcriptome RNA sequencing data from thyroid nodules analyzed with the Afirma GSC.
- “The abstracts to be presented by our clinical research colleagues at the ATA meeting show that the Afirma GSC platform can be used to glean new insights about thyroid nodules and thyroid cancer preoperatively.
- We believe that Afirma-based whole-transcriptome analysis will help drive cancer research and unlock findings that may ultimately be used in clinical care.”
These abstracts will later be published as an online supplement to Thyroid, the official journal of the ATA.